Clinical Trials Sponsored by Vaccinex Inc

Total 36201 results

Vaccinex Inc.
PPD

Completed

Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors

Solid Tumors

United States
Emory University
Vaccinex Inc.

Recruiting

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
VBI Vaccines Inc.

Recruiting

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Glioblastoma Multiforme

United States
VBI Vaccines Inc.

Withdrawn

Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant

Coronavirus Infections | COVID-19

Canada
VBI Vaccines Inc.

Completed

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a

Covid19

Canada
Rational Vaccines Inc

Completed

A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease

Patient Engagement | Genital Herpes

United Kingdom
VBI Vaccines Inc.

Completed

A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults

Hepatitis B

Vietnam
VBI Vaccines Inc.

Completed

A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™

Hepatitis B
Meissa Vaccines, Inc.

Completed

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

Respiratory Syncytial Virus Infections

United States
VBI Vaccines Inc.

Completed

Lot-to-lot Consistency of Sci-B-Vac™ in Adults

Hepatitis B Vaccines

United States, United Kingdom, Finland, Belgium, Canada, Germany
Meissa Vaccines, Inc.

Completed

Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

Respiratory Syncytial Virus Infections

United States
VBI Vaccines Inc.

Recruiting

PREHEVBRIO Pregnancy Outcomes Registry

Vaccine Exposure During Pregnancy

United States
Meissa Vaccines, Inc.

Recruiting

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

Covid19

United States
VBI Vaccines Inc.

Active, not recruiting

Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a

Coronavirus Infections | COVID-19

Canada
VBI Vaccines Inc.

Completed

Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®

Hepatitis B

Russian Federation
VBI Vaccines Inc.

Completed

Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults

Hepatitis B Vaccines

United States, Canada, Finland, Belgium
Meissa Vaccines, Inc.

Recruiting

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Respiratory Syncytial Virus (RSV)

United States
Vaccine Company, Inc.

Active, not recruiting

Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa

SARS-CoV-2 | SARS-CoV

South Africa
Vaccine Company, Inc.

Active, not recruiting

Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States

SARS-CoV-2 | SARS-CoV

United States
Vaccinex Inc.
University of Rochester

Recruiting

Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma

United States
Vaccinex Inc.
Huntington Study Group

Completed

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi (SIGNAL-HD)

Huntington's Disease

United States, Canada
Vaccinex Inc.
PRA Health Sciences

Completed

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

Multiple Sclerosis

United States
Meissa Vaccines, Inc.
Hvivo

Completed

Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine

RSV Infection

United Kingdom
International Vaccine Institute
Siriraj Hospital; Vaccine Technologies Inc.

Completed

Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults

Diarrhea | Cholera | Vibrio Infections

Thailand
Vaccinex Inc.
Merck Sharp & Dohme LLC

Recruiting

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

United States
Vaccinex Inc.
Merck KGaA, Darmstadt, Germany

Completed

VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer (CLASSICAL-Lung)

Carcinoma, Non-Small-Cell Lung

United States
International AIDS Vaccine Initiative
Auro Vaccines LLC; Ichor Medical Systems Incorporated

Completed

Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers

HIV Infections

Rwanda, Uganda, Kenya
Global Research Institute
Rational Vaccines Inc

Recruiting

A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects (HSVHIV)

HIV Disease | Herpes Simplex 2 | Herpes Simplex 1

United States
Vaccinex Inc.
Alzheimer's Association; Alzheimer's Drug Discovery Foundation

Active, not recruiting

SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD) (SIGNAL-AD)

Alzheimer Disease

United States
Novartis Vaccines
Novartis Vaccines and Diagnostics (formerly Chiron Vaccines)

Completed

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

Influenza Disease; Flu

United States
GPN Vaccines

Recruiting

Extension Safety and Immunogenicity Study of GPNV-001

Pneumococcal Infections

Australia
Brii Biosciences Limited
VBI Vaccines Inc.; Vir Biotechnology, Inc.

Completed

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic HBV Infection

Hepatitis B, Chronic

Australia, China, Korea, Republic of, New Zealand, Singapore, Thailand
GPN Vaccines

Recruiting

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

Pneumococcal Infections

Australia
THEVAX Genetics Vaccine
Clinical Research Management, Inc.

Unknown

Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

Human Papillomavirus | High-Grade Squamous Intraepithelial Lesions

United States
VBI Vaccines Inc.
Clinical Trial Data Services, LLC

Completed

Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults

Cytomegalovirus Infections

Canada
Novartis Vaccines
Novartis Vaccines and Diagnostics S.r.l.

Completed

Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly

Influenza

Poland
Novartis Vaccines

Completed

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Influenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza Virus

Belgium
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
Novartis Vaccines

Completed

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

Influenza

Finland, United States, Poland
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

Meningococcal Disease

United Kingdom
Novartis Vaccines

Completed

Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

Meningococcal Meningitis

Canada
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

Influenza

United States, Finland, Philippines, Thailand
Novartis Vaccines
Novartis

Completed

Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

Prevention of Meningococcal Disease

United States
Novartis Vaccines

Completed

Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine

Meningococcal Disease

Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age

Hepatitis B | Pertussis | Tetanus | Diphtheria | Hemophilus Influenzae B

India
Novartis Vaccines

Completed

A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications

Influenza

Italy, Spain
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects

Influenza | Seasonal Influenza

United Kingdom
Novartis Vaccines

Completed

Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine

Swine-Origin Influenza A H1N1 Virus

Japan
Novartis Vaccines

Completed

Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults

Helicobacter Pylori Infection

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Germany

3

Subscribe